| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b7edd3693b55c0fd41df267c299f173 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-78 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-78 |
| filingDate |
2003-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b22427779cc5d516ddaca69c9e2d1af7 |
| publicationDate |
2003-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-03100027-A2 |
| titleOfInvention |
Mutant fibronectin and tumor metastasis |
| abstract |
The present invention relates to a mutated fibronectin as a class II-restricted tumor antigen recognized by tumor-reactive CD4+ T cells. In a specific embodiment, the mutation in fibronectin is responsible for the loss of FN matrix formation, leading to the enhanced migration of tumor cells. This provides an exemplary important immune target for effective cancer immunotherapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102005041616-B4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102005041616-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102005041616-A8 |
| priorityDate |
2002-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |